Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-part, FiH Study in Healthy Participants and Participants With Atopic Dermatitis (AD) to Assess the Safety, Tolerability, Pharmacokinetics (PK) of Single & Multiple Ascending Doses and Selected Dose of SYX-5219 (AD Participants).

NCT07558668 is registered in ClinicalTrials.gov with Sitryx Therapeutics Ltd as lead sponsor.

NCT NCT07558668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07558668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-part, FiH Study in Healthy Participants and Participants With Atopic Dermatitis (AD) to Assess the Safety, Tolerability, Pharmacokinetics (PK) of Single & Multiple Ascending Doses and Selected Dose of SYX-5219 (AD Participants).
Lead sponsor
Sitryx Therapeutics Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
February 26, 2025
Completion date
September 30, 2026
Enrollment
149 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe atopic dermatitis